PharmacyCodes



Cardioquin en es it fr

Categoria

Cardioquin Nombres de marca, Cardioquin Analogos

Cardioquin Marca los nombres de mezcla

  • No information avaliable

    • Cardioquin Formula quimica

    C20H24N2O2

    Cardioquin RX enlace

    http://www.rxlist.com/cgi/generic/quinidine.htm

    Cardioquin FDA hoja

    Cardioquin FDA

    Cardioquin MSDS (hoja de seguridad de materiales)

    Cardioquin Sintesis de referencia

    No hay información disponible

    Cardioquin Peso molecular

    324.417 g/mol

    Cardioquin Punto de fusion

    174 oC

    Cardioquin H2O Solubilidad

    140 mg / L

    Cardioquin Estado

    Solid

    Cardioquin LogP

    2.534

    Cardioquin Formas de dosificacion

    Solución

    Cardioquin Indicacion

    Para el tratamiento de pre-excitación ventricular y arritmias cardíacas

    Cardioquin Farmacologia

    Quinidina, un anticonvulsivo fenitoína, se usa solo o junto con fenobarbital u otros anticonvulsivos para gestionar crisis tónico-clónicas, ataques psicomotores, los síndromes de dolor neuropático diabético incluyendo neuropatía, inducidas por digitálicos arritmias cardíacas y arritmias cardíacas asociadas con prolongación del intervalo QT.

    Cardioquin Absorcion

    No hay información disponible

    Cardioquin Toxicidad

    No hay información disponible

    Cardioquin Informacion de Pacientes

    Before prescribing QUINAGLUTE® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected. Discussion should include the facts

    • that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
    • that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
    • that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
    • that such data as are available suggest that treatment with QUINAGLUTE® is likely to increase the patient's risk of death.

    To confirm whether this is the most current prescribing information available on Quinaglute®, or to obtain the most current prescribing information, please call Berlex Laboratories at 1-888-BERLEX-4 (choose option #4, Product Usage Information).

    Cardioquin Organismos afectados

    Humanos y otros mamíferos